1. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients 
Alaa Rostom, Lawrence Goldkind, Loren Laine 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 5, Pages (May 2005)
DOI: /S (04)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Proportion of patients (and 95% CI) with aminotransferase elevations >3× ULN for individual NSAIDs. (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Proportion of patients (and 95% CI) with liver-related discontinuations from the studies for individual NSAIDs. (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Proportion of patients (and 95% CI) with hepatic SAEs for individual NSAIDs. (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
Proportion of patients (and 95% CI) with aminotransferase elevations >3× ULN for individual NSAIDs in shorter-term studies (≤13 wk) vs longer-term studies (>13 wk). (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
Proportion of patients (and 95% CI) with liver-related discontinuations from the studies for individual NSAIDs in shorter-term studies (≤13 wk) vs longer-term studies (>13 wk). (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

7. Figure 6
Proportion of patients (and 95% CI) with aminotransferase elevations >3× ULN for lower-dose vs higher-dose diclofenac and rofecoxib. (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

8. Figure 7
Proportion of patients (and 95% CI) with liver-related discontinuations from the studies for lower-dose vs higher-dose diclofenac and rofecoxib. (Total number of patients exposed listed below each NSAID.)
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions